Clinical Trials Logo

Clinical Trial Details — Status: Enrolling by invitation

Administrative data

NCT number NCT04941456
Other study ID # 202104CUT
Secondary ID
Status Enrolling by invitation
Phase N/A
First received
Last updated
Start date July 29, 2021
Est. completion date January 31, 2025

Study information

Verified date February 2024
Source Gaylord Hospital, Inc
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to determine if the use of the Passy-Muir Valve improves endurance for patients in the Long Term Acute Care setting as measured with the Six- Minute Walk Test.


Description:

A Passy-Muir Valve (PMV) is a one-way valve that blocks air flow from exhalation in patients with a tracheostomy, and redirects it through to the upper airway to enable functional use of the glottis. Typically, PMVs are used to assist patients being weaned from mechanical ventilation to communicate more effectively after tracheostomy. Devices are available that can be used in-line with the ventilator, as well as after ventilator liberation with a tracheostomy collar. PMVs provide patients with the ability to communicate, swallow, and improve diaphragmatic strength, which lengthens the periods of time that patients remain free from ventilator assistance, which ultimately leads to decannulation. Use of the PMV during physical therapy helps restore the pressure support in the trunk, allowing for natural increases in intra-thoracic pressure (ITP) and intra-abdominal pressures (IAP) in response to increased postural demands. With an open tracheostomy tube and therefore, an open system, thoracic pressures cannot be increased or sustained as airflow passes through the tracheostomy tube and bypasses the upper airway. This difficulty would be observed when a patient needs to crawl, sit, push, or stand up. The typical means of gross motor movement for mobility is to engage the glottis (vocal cords) to restrict the expiratory lung volume in order to stabilize the chest and upper body. Placing a PMV on the tracheostomy tube closes the system and restores a patient's ability to use the upper airway to control expiratory flow and improve ITP and IAP. The Six-Minute Walk Test (6MWT) is a commonly used test for the objective assessment of functional exercise capacity for management of patients with moderate to severe pulmonary disease. The patient is asked to walk as far as possible along a 30 meter minimally trafficked corridor for a period of six minutes. The 6MWT is a safe test with rare complications, the most common adverse event is oxygen desaturation below 80%. Participants will consist of inpatients with tracheostomy who can tolerate use of Passy-Muir Valve; participants will be approached and consented into the study within 72 hours of being deemed medically appropriate for PMV use by medical staff. The 6MWT will be administered each session to assess ambulation distance, alternating open tracheostomy vs Passy-Muir Valve in place on sequential days to compare results. The Borg Rating of Perceived Exertion (RPE) scale will be administered before and after each session to assess patient's subjective rating of physical exertion levels on a scale from 6 through 20; 20 being the most exertion possible. Oxygen saturation and heart rate will be monitored before and after each session via pulse oximeter to assess for physiologic appropriateness of exercise response. For safety of the participant, while performing the six-minute walk test, participants will be allowed to use assistive devices as prescribed by the participant's primary physical therapist. Sample size: A convenience sample of 30 participants will be collected. Data: All data will be collected and analyzed in a paired fashion as appropriate; adjustments for abnormal distribution, unequal variance, and repeated measure will be applied as necessary. In the case of missing or inconsistent data due to early withdraw, early participant discharge, or other unforeseen events, the datasets will be evaluated as normal. Paired T-test and Repeated Measures Analysis of Variance (ANOVA) will be conducted to evaluate differences in Borg RPE scores and six-minute walk tests, between treatment arms, as appropriate. Correlation analysis may also be conducted to evaluate if there is any correlation to treatment arm, Borg RPE scores, six-minute walk test, and other variables such as session number.


Recruitment information / eligibility

Status Enrolling by invitation
Enrollment 30
Est. completion date January 31, 2025
Est. primary completion date January 31, 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Individual with tracheostomy who can tolerate daily 30 minute Physical Therapy sessions with use of PMV and be able to maintain oxygen saturations above 88% with exertion. 2. Ability to understand and respond to simple verbal instructions and one step commands in English well enough to consent without any interpretation. 3. Ability to ambulate a minimum of 10 feet with/without assistive device and with/without physical assistance. Exclusion Criteria: 1. Active seizures 2. Active Pregnancy 3. Uncontrolled hypertension 4. Cognitive deficits that would disrupt ability to provide informed consent 5. Enteric infection control precautions 6. Ongoing orthostasis 7. Actively on decannulation protocol 8. Medical instability that would cause a doctor to put therapy program on hold

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Open Tracheostomy
Participants will perform the six minute walk test with an open tracheostomy. Participants will complete 1 to 3 session over approximately three-weeks.
Device:
PMV in place
Participants will perform the six minute walk test with a PMV in place. Participants will complete 1 to 3 sessions over approximately three-weeks.

Locations

Country Name City State
United States Gaylord Hospital Wallingford Connecticut

Sponsors (1)

Lead Sponsor Collaborator
Gaylord Hospital, Inc

Country where clinical trial is conducted

United States, 

References & Publications (4)

Agarwala P, Salzman SH. Six-Minute Walk Test: Clinical Role, Technique, Coding, and Reimbursement. Chest. 2020 Mar;157(3):603-611. doi: 10.1016/j.chest.2019.10.014. Epub 2019 Nov 2. — View Citation

Ceron C, Otto D, Signorini AV, Beck MC, Camilis M, Sganzerla D, Rosa RG, Teixeira C. The Effect of Speaking Valves on ICU Mobility of Individuals With Tracheostomy. Respir Care. 2020 Feb;65(2):144-149. doi: 10.4187/respcare.06768. Epub 2019 Oct 15. — View Citation

Massery M, Hagins M, Stafford R, Moerchen V, Hodges PW. Effect of airway control by glottal structures on postural stability. J Appl Physiol (1985). 2013 Aug 15;115(4):483-90. doi: 10.1152/japplphysiol.01226.2012. Epub 2013 Jun 13. — View Citation

Roberts KJ. Enhancing Early Mobility With a Speaking Valve. Respir Care. 2020 Feb;65(2):269-270. doi: 10.4187/respcare.07671. No abstract available. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Six Minute Walk Test - Session 1 During each session, Participants will be asked to walk as far as possible along a corridor for a period of six minutes. The distance the Participant walks will be recorded to compare if the Participant can walk further with or without the PMV in place. Participant can use a device to assist with balance and the Participant can be assisted by an investigator, if needed. Each session is scheduled in an alternating fashion for whether or not Participant will use the PMV (i.e. day one no PMV, day two with PMV, day three no PMV, day four with PMV). Participants will complete 3 sessions with the PMV in place and 3 sessions with an open tracheostomy. Study sessions will occur on consecutive days, five days a week, Monday through Friday, until a minimum of 2 to maximum of 6 sessions are completed. The first study session (Day 1) will occur within 72 hours of the participant being cleared by Medical Staff for PMV use.
Primary Six Minute Walk Test - Session 2 During each session, Participants will be asked to walk as far as possible along a corridor for a period of six minutes. The distance the Participant walks will be recorded to compare if the Participant can walk further with or without the PMV in place. Participant can use a device to assist with balance and the Participant can be assisted by an investigator, if needed. Each session is scheduled in an alternating fashion for whether or not Participant will use the PMV (i.e. day one no PMV, day two with PMV, day three no PMV, day four with PMV). Participants will complete 3 sessions with the PMV in place and 3 sessions with an open tracheostomy. Study sessions will occur on consecutive days, five days a week, Monday through Friday, until a minimum of 2 to maximum of 6 sessions are completed. The second study session (Day 2) will occur the day following the first session (Day 1).
Primary Six Minute Walk Test - Session 3 During each session, Participants will be asked to walk as far as possible along a corridor for a period of six minutes. The distance the Participant walks will be recorded to compare if the Participant can walk further with or without the PMV in place. Participant can use a device to assist with balance and the Participant can be assisted by an investigator, if needed. Each session is scheduled in an alternating fashion for whether or not Participant will use the PMV (i.e. day one no PMV, day two with PMV, day three no PMV, day four with PMV). Participants will complete 3 sessions with the PMV in place and 3 sessions with an open tracheostomy. Study sessions will occur on consecutive days, five days a week, Monday through Friday, until a minimum of 2 to maximum of 6 sessions are completed. The third study session (Day 3) will occur the day following the second session (Day 2).
Primary Six Minute Walk Test - Session 4 During each session, Participants will be asked to walk as far as possible along a corridor for a period of six minutes. The distance the Participant walks will be recorded to compare if the Participant can walk further with or without the PMV in place. Participant can use a device to assist with balance and the Participant can be assisted by an investigator, if needed. Each session is scheduled in an alternating fashion for whether or not Participant will use the PMV (i.e. day one no PMV, day two with PMV, day three no PMV, day four with PMV). Participants will complete 3 sessions with the PMV in place and 3 sessions with an open tracheostomy. Study sessions will occur on consecutive days, five days a week, Monday through Friday, until a minimum of 2 to maximum of 6 sessions are completed. The fourth study session (Day 4) will occur the day following the third session (Day 3).
Primary Six Minute Walk Test - Session 5 During each session, Participants will be asked to walk as far as possible along a corridor for a period of six minutes. The distance the Participant walks will be recorded to compare if the Participant can walk further with or without the PMV in place. Participant can use a device to assist with balance and the Participant can be assisted by an investigator, if needed. Each session is scheduled in an alternating fashion for whether or not Participant will use the PMV (i.e. day one no PMV, day two with PMV, day three no PMV, day four with PMV). Participants will complete 3 sessions with the PMV in place and 3 sessions with an open tracheostomy. Study sessions will occur on consecutive days, five days a week, Monday through Friday, until a minimum of 2 to maximum of 6 sessions are completed. The fifth study session (Day 5) will occur the day following the fourth session (Day 4).
Primary Six Minute Walk Test - Session 6 During each session, Participants will be asked to walk as far as possible along a corridor for a period of six minutes. The distance the Participant walks will be recorded to compare if the Participant can walk further with or without the PMV in place. Participant can use a device to assist with balance and the Participant can be assisted by an investigator, if needed. Each session is scheduled in an alternating fashion for whether or not Participant will use the PMV (i.e. day one no PMV, day two with PMV, day three no PMV, day four with PMV). Participants will complete 3 sessions with the PMV in place and 3 sessions with an open tracheostomy. Study sessions will occur on consecutive days, five days a week, Monday through Friday, until a minimum of 2 to maximum of 6 sessions are completed. The sixth study session (Day 6) will occur the day following the fifth session (Day 5).
Primary Average Change of Borg Rating of Perceived Exertion - Session 1 (Day 1) Borg Rating of Perceived Exertion is a self reported outcome score, based on a scale of 6 through 20 (20 being the hardest or most exertion, 6 being the least exertion).
The first session will occur within 72 hours of the participant being cleared by Medical Staff for PMV use. Subsequent sessions will occur on every consecutive day following for 6 days total, Monday through Friday, until a minimum of 2 to maximum of 6 sessions are completed.
The first study session (Day 1 ) will occur within 72 hours of the participant being cleared by Medical Staff for PMV use.
Primary Average Change of Borg Rating of Perceived Exertion - Session 2 (Day 2) Borg Rating of Perceived Exertion is a self reported outcome score, based on a scale of 6 through 20 (20 being the hardest or most exertion, 6 being the least exertion).
The first session will occur within 72 hours of the participant being cleared by Medical Staff for PMV use. Subsequent sessions will occur on every consecutive day following for 6 days total, Monday through Friday, until a minimum of 2 to maximum of 6 sessions are completed.
The second study session (Day 2) will occur the day following the first study session (Day 1) .
Primary Average Change of Borg Rating of Perceived Exertion - Session 3 (Day 3) Borg Rating of Perceived Exertion is a self reported outcome score, based on a scale of 6 through 20 (20 being the hardest or most exertion, 6 being the least exertion).
The first session will occur within 72 hours of the participant being cleared by Medical Staff for PMV use. Subsequent sessions will occur on every consecutive day following for 6 days total, Monday through Friday, until a minimum of 2 to maximum of 6 sessions are completed.
The third study session (Day 3) will occur the day following the second study session (Day 2) .
Primary Average Change of Borg Rating of Perceived Exertion - Session 4 (Day 4) Borg Rating of Perceived Exertion is a self reported outcome score, based on a scale of 6 through 20 (20 being the hardest or most exertion, 6 being the least exertion).
The first session will occur within 72 hours of the participant being cleared by Medical Staff for PMV use. Subsequent sessions will occur on every consecutive day following for 6 days total, Monday through Friday, until a minimum of 2 to maximum of 6 sessions are completed.
The fourth study session (Day 4) will occur the day following the third study session (Day 3) .
Primary Average change of Borg Rating of Perceived Exertion - Session 5 (Day 5) Borg Rating of Perceived Exertion is a self reported outcome score, based on a scale of 6 through 20 (20 being the hardest or most exertion, 6 being the least exertion).
The first session will occur within 72 hours of the participant being cleared by Medical Staff for PMV use. Subsequent sessions will occur on every consecutive day following for 6 days total, Monday through Friday, until a minimum of 2 to maximum of 6 sessions are completed.
The fifth study session (Day 5) will occur the day following the fourth study session (Day 4) .
Primary Average Change of Borg Rating of Perceived Exertion - Session 6 (Day 6) Borg Rating of Perceived Exertion is a self reported outcome score, based on a scale of 6 through 20 (20 being the hardest or most exertion, 6 being the least exertion).
The first session will occur within 72 hours of the participant being cleared by Medical Staff for PMV use. Subsequent sessions will occur on every consecutive day following for 6 days total, Monday through Friday, until a minimum of 2 to maximum of 6 sessions are completed.
The sixth study session (Day 6) will occur the day following the fifth study session (Day 5) .
Secondary Heart Rate Using a finger pulse-oxygen meter. Participant heart rate will be measured just prior and immediately after each intervention.
Secondary Oxygen Saturation Using a finger pulse-oxygen meter. Participant oxygen saturation will be measured just prior and immediately after each intervention.
Secondary Active standing time The duration of active standing time, including standing rest breaks and active ambulation, that participants are able to tolerate while completing the six-minute walk test will be recorded. Participant active standing time will be recorded immediately after each intervention.
See also
  Status Clinical Trial Phase
Completed NCT02116608 - Treatment of Tracheostomy Granulomas Phase 4
Not yet recruiting NCT06375369 - Digital Health Pathway for Children With Medical Complexity Requiring Tracheostomy N/A
Completed NCT01976819 - Clinical Assessment of New Speaking Valve With Heat and Moisture Exchanger (HME) for Tracheotomized Patients N/A
Terminated NCT00323986 - Azithromycin Treatment of Patients With Chronic Obstructive Pulmonary Disease (COPD) and Tracheostomy Phase 2
Not yet recruiting NCT06236542 - Tracheostomy Robotics and Cutting-edge Health Education for Airway Safety N/A
Completed NCT03955874 - Mechanical Ventilation Discontinuation Practices
Completed NCT04668742 - Efficacy and Safety of the DYNAtraq Device to Prevent Complications in Tracheostomy in Mechanically Ventilated Patients N/A
Recruiting NCT05047432 - Concordance of Methods to Select Tracheostomy Tube Size for Adults in Intensive Care
Recruiting NCT06120790 - Investigation of a 3 oz Water Protocol on Patients With Tracheostomies
Withdrawn NCT05658029 - An Investigator-initiated Study to Evaluate Safety and Efficacy of ARINA-1 in People With a Tracheostomy Phase 1
Active, not recruiting NCT05041894 - Effect of Body Tilting on Diaphragm Excursion and Thickness in the Stroke Patients With Tracheotomy by Ultrasonography
Active, not recruiting NCT02990871 - Efficacy of an Early Rehabilitation on Decannulation Time of Patients With Severe Acquired Brain Injury N/A
Enrolling by invitation NCT06283953 - Boosting Resources for Tracheostomy Care at Home N/A
Not yet recruiting NCT04872881 - Comparison of Effectiveness of Different Airway Management Methods During Percutaneous Tracheostomy Phase 4
Completed NCT02512744 - Reducing Decannulation Time: Limitation of Decannulation Capping Trials (REDECAP) N/A
Recruiting NCT04642703 - Mortality in Patients With Severe COVID-19 Pneumonia Who Underwent Tracheostomy
Completed NCT04447638 - Percutaneous Tracheostomy With COVID-19
Completed NCT05434442 - Caregivers Tracheal Aspiration Training N/A
Not yet recruiting NCT06431048 - No DIET Trial: Dogmatic Interruption of Enteral nuTrition N/A
Recruiting NCT02469909 - Comparison Between Immediate and Gradual Decannulation N/A